Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its holdings in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) by 250.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 37,619 shares of the company’s stock after purchasing an additional 26,893 shares during the period. JPMorgan Chase & Co.’s holdings in Artiva Biotherapeutics were worth $379,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in ARTV. China Universal Asset Management Co. Ltd. bought a new stake in Artiva Biotherapeutics during the fourth quarter worth approximately $52,000. Barclays PLC purchased a new position in Artiva Biotherapeutics during the 3rd quarter valued at about $304,000. Charles Schwab Investment Management Inc. increased its stake in shares of Artiva Biotherapeutics by 8.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock worth $439,000 after acquiring an additional 3,233 shares during the last quarter. State Street Corp purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth about $1,337,000. Finally, Geode Capital Management LLC bought a new stake in Artiva Biotherapeutics in the third quarter worth approximately $4,774,000.

Artiva Biotherapeutics Trading Down 0.8 %

NASDAQ ARTV opened at $2.37 on Friday. The stock has a 50-day simple moving average of $3.41 and a 200 day simple moving average of $7.28. Artiva Biotherapeutics, Inc. has a 12 month low of $1.78 and a 12 month high of $17.31.

Analysts Set New Price Targets

Several brokerages have commented on ARTV. Cantor Fitzgerald lowered their price target on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, March 25th. Wedbush reiterated an “outperform” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday, April 8th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Artiva Biotherapeutics has a consensus rating of “Buy” and an average target price of $20.40.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.